Canine IMHA: Diagnostic Workup and Test Interpretation

Bottom line

A defensible canine IMHA diagnosis combines anemia, immune-mediated erythrocyte destruction and hemolysis, rather than treating one positive screening test as the entire diagnosis. The ACVIM consensus also separates identifying a comorbidity from proving that it caused the anemia. [1] Preserve that distinction before committing the patient to a prolonged immune-mediated disease label.

Confirm the anemia and the immediate support needs

Assess perfusion, mentation, respiratory effort and the trajectory of anemia while arranging diagnostic sampling. Decide which support cannot wait and which samples can be preserved without delaying necessary care. Record treatments already given before referral.

ACVIM suggests a spun PCV when agglutination makes calculated hematocrit unreliable, while acknowledging limitations of PCV measurement. Lack of regeneration does not exclude IMHA. [1] Compare the analyzer result, smear and clinical findings rather than resolving a discrepancy by choosing whichever value best fits the suspected diagnosis.

Keep blood loss and mixed mechanisms visible. The canine hemostasis workup addresses platelet and coagulation abnormalities when bleeding could contribute. The canine ITP management reference develops the separate platelet-destruction question; anemia plus thrombocytopenia should not automatically be assigned one immune mechanism.

Document immune evidence and hemolysis separately

The consensus algorithm supports a firm diagnosis with anemia, at least two immune-destruction markers or a saline agglutination test that remains positive after washing, and at least one sign of hemolysis. [1] Record the actual combination present, not simply “Coombs positive” or “autoagglutination.”

Assess spherocytes in an appropriate smear area and consider competing causes of abnormal erythrocyte morphology. For bilirubin abnormalities, retain hepatobiliary disease and sepsis in the differential; for hemoglobinemia, exclude sample-related hemolysis before treating it as in-vivo destruction. [1]

Make the uncertainty explicit when the findings are supportive rather than definitive. A provisional diagnosis can guide urgent decisions without turning an incomplete pattern into permanent proof. Ask the clinical pathologist to help resolve discordant findings before interpreting every subsequent change as immune-mediated relapse.

Treat saline agglutination as a method-dependent test

A prospective diagnostic-accuracy study in anemic referral dogs found that higher saline-to-blood ratios improved specificity. Its immune-mediated hemolysis reference classification required a positive gel DAT plus clinical evidence of hemolysis, and the number of reference-positive dogs was small. [2]

This is a reason to standardize and document the method, not to assume every negative diluted test excludes IMHA. A screen using one dilution, persistent agglutination after washing, and an impression of clumping on an ordinary smear are different observations.

Record sample quality, the laboratory procedure, whether the result was equivocal and whether washing changed it. Use the performing laboratory's validated process rather than copying an undocumented bedside mixture. If the result conflicts with the remainder of the assessment, arrange confirmatory testing and review the original material.

Interpret DAT and comparative-test evidence at the right level

A prospective comparative survey examined samples submitted for DAT testing together with healthy controls. Different DAT methods showed broadly comparable results, while much observed macroscopic agglutination disappeared after saline washing. [3]

The selected submitted-sample population, incomplete clinical follow-up and lack of a universal independent reference standard limit what test agreement establishes. The study supports careful immunohematological testing; it does not make every positive result a complete clinical diagnosis. [3]

Use the report to identify antibody-coated cells in context. Do not equate an immunohematological finding with proof that all current anemia is caused by active immune destruction. Preserve alternative explanations when the hematological trajectory and test result do not agree.

Preserve pretreatment samples when feasible

ACVIM recommends collecting DAT samples before immunosuppressive treatment and before transfusion where possible. A previous transfusion does not absolutely prevent testing, but its timing matters to interpretation. [1]

Coordinate tube type, sample handling and shipping with the laboratory. Include the transfusion and medication timeline on the request. Diagnostic sampling should be organized promptly alongside stabilization rather than becoming a reason to withhold necessary support.

Investigate association without declaring causation

The consensus recommends a thorough exposure and medication history, examination, CBC and blood-film review, biochemistry and urinalysis, with further investigations directed by the individual case. It proposes “associative” and “non-associative” terminology to avoid implying that a detected comorbidity is necessarily causal or that every possible trigger has been excluded. [1]

Review travel, vector exposure, prior drugs, vaccination and possible infectious or neoplastic disease. Specify which finding would change treatment and which positive screening result requires confirmation. A history item temporally preceding anemia is a lead to investigate, not sufficient causal evidence by itself.

For follow-up, keep the original diagnostic basis available. The comparative study documented persistent DAT positivity during treatment in some dogs. [3] Reassess anemia, hemolysis and the current clinical problem together rather than allowing an isolated persistent test result to dictate disease activity or treatment escalation.

Frequently Asked Questions

Does anemia with a positive agglutination screen automatically establish IMHA?

No. The ACVIM framework combines anemia, evidence of immune-mediated destruction and evidence of hemolysis; an unqualified screening result is insufficient. [1]

Can absence of regeneration exclude IMHA?

No. The consensus recognizes nonregenerative presentations and does not use regeneration as an exclusion requirement. [1]

Why does the saline agglutination method need to be recorded?

In a prospective diagnostic-accuracy study, specificity improved as the saline-to-blood ratio increased. The method and dilution therefore affect interpretation. [2]

Does agreement among DAT methods prove every test is perfectly accurate?

No. The comparative study evaluated selected submitted samples and lacked a universally accepted independent gold standard. Agreement is not universal sensitivity or specificity. [3]

Should samples be collected before treatment and transfusion?

Where feasible, ACVIM recommends obtaining DAT samples before immunosuppressive treatment and transfusion. Prior transfusion is not an absolute contraindication to subsequent testing. [1]

Does a positive DAT prove active hemolysis at every follow-up?

No. DAT positivity persisted during treatment in some dogs in the comparative study, so it must be interpreted with the current hematological and clinical findings. [3]

Does finding a comorbidity prove that it caused IMHA?

No. The consensus proposes associative terminology because a detected comorbidity can be causal or coincidental. [1]